AUPH · Aurinia Pharmaceuticals Inc
AI read · Good for AUPH
The AI's read
Aurinia struck a settlement with Teva that upholds two U.S. patents and bars Teva’s generic voclosporin until at least Dec. 7, 2036. That preserves exclusivity for Lupkynis and removes the main generic threat for years. The market already reacted, lifting AUPH roughly 9.5% premarket, so immediate relief is priced. The stock sits below its 52-week high, so upside exists but looks limited versus the magnitude of the patent win. We lean bullish: the deal materially de-risks Aurinia’s core product and confirms patent strength. Conviction 90%; company-specific win, but position sizing should be modest given limited near-term upside.